We have to differentiate among the three diseases.
For AIDS, where the biggest budget is in terms of antiretroviral drugs, we purchase 90% of those as generics and the bulk of that comes from India. India has a very vibrant generic industry of high quality, because it's not only the price; it's also the assured quality. Almost 90% of that we purchase in India, some from South Africa and other countries, but largely they're generic drugs.
When you come to tuberculosis, the first-line treatment is drugs that have been used for decades, so they are all off patent and therefore relatively cheap. We buy a complete course of TB treatment for six months. It costs about $50. That's generic drugs because there's no patent on these drugs. The challenge comes when we get to the more resistant forms. If we have to treat multidrug-resistant tuberculosis, then we have to go to new drugs that have been developed that are much more expensive and also more difficult to administer, and we have to buy them from research-based pharmaceutical companies.
For malaria, by the way, it's a mix. The artemisinin combination therapy is still under patent, but we get it at a largely reduced price. That's the tiered pricing that is coming in here.
It differs a little bit among the three diseases, but for the first-line treatment, we can buy them at very competitive prices, largely from generic producers.